secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001157523-22-001569
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q3 LIVMARLI sales $18.8M; raises FY2022 guidance to $70M
--------------------------------------------------------------

- Net product sales LIVMARLI $18.8M in Q3; YTD $47.2M; raised FY2022 guidance to $70M.
- Reported Q3 net loss $35.7M ($1.02/share) vs $47.1M loss ($1.55/share) in Q3 2021.
- Positive CHMP opinion for LIVMARLI in Alagille syndrome; EU decision expected Q4 2022.
- Positive Phase 3 MARCH data in PFIC; completed public offering netting $86.1M.
- Cash $285.3M at Sept 30; upcoming data: EMBARK Ph2b H2 2023, OHANA Ph2b H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/0001157523-22-001569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000115752322001569/a52964746.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer